Related Experiment Video
Updated: Aug 14, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
[Molecular biology in the diagnosis of lung cancer]
1Toksikologisk seksjon, Statens arbeidsmiljøinstitutt, Postboks 8149 Dep, 0033 Oslo. age.haugen@stami.no
Background:
Lung cancer is the most prevalent and deadly cancer in the world. Despite extensive efforts made in the development of diagnostic methods, the overall five-year survival rate remains low.
Materials And Methods:
Research articles and reviews.
Results And Interpretation:
Significant progress has been made in understanding the molecular and cellular mechanisms and pathogenesis in lung cancer. In addition to abnormalities in proto-oncogenes and tumour suppressor genes, aberrant promoter hypermethylation is now recognised as an important component in lung cancer progression. Sensitive assays have been developed to assess promoter methylation in biological fluids that may be used in screening programmes and diagnosis of lung cancer. The development of gene expression profiling techniques has led to new approaches to lung cancer classification and diagnosis.
